Posted by Michael Wonder on 31 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion in Ontario
29 August 2025 - Roche Canada is pleased to announce today that Vabysmo (faricimab injection) is now publicly funded for macular oedema secondary to retinal vein occlusion on the Ontario Drug Benefit Program.
Vabysmo received Health Canada authorisation for treatment of macular oedema secondary to retinal vein occlusion in July 2024.
